Update in the treatment of herpes zoster;Actualización en el tratamiento del herpes zóster

Actas Dermo-Sifiliograficas

Volumn 97, Issue 2, 2006, Pages 103-114

  España, Agustín ^a   Redondo, Pedro ^a  

^a UNIVERSITY CLINIC OF NAVARRA   (Spain)

Author keywords

Aciclovir; Brivudine; Herpes zoster; Neuralgia; Treatment

Indexed keywords

5 (2 BROMOVINYL) 2' DEOXYURIDINE; ACICLOVIR; AMITRIPTYLINE; ANALGESIC AGENT; CAPSAICIN; CORTICOSTEROID; FAMCICLOVIR; FLUOROURACIL; GABAPENTIN; LIDOCAINE; VALACICLOVIR;

ANALGESIA; DRUG APPROVAL; DRUG EFFICACY; HEALING; HERPES ZOSTER; HUMAN; IMMUNE DEFICIENCY; PAIN PARAMETERS; REVIEW; SKIN PAIN; VARICELLA ZOSTER VIRUS;

EID: 33646512437     PISSN: 00017310     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0001-7310(06)73360-9     Document Type: Article

References (112)

1. Straus SE, Oxman MN. Varicella and herpes zoster. En: Freedberg IM, Eisen AZ, Wolff K, et al, editors. Fitzpatrick's Dermatology in General Medicina. New York: McGraw-Hill; 1999. p. 2427-50.
2. Lilie HM, Wassilew SW. The role of antivirials in the management of neuropathic pain in the older patient with herpes zoster. Drugs Aging. 2003;20:561-70.
3. International Herpes Management Forum. Recommendations categories, pg 3. Disponible en: http://www.IHMF.org
4. Gross G. Zoster. The manifestation forms in the skin, complications and therapy. Dtsch Med Wochenschr. 1997;122: 132-9.
5. Wildenhoff KE, Esmann V, Ipsen J, Harving H, Peterslund NA, Schonheyder H. Treatment of trigeminal and thoracic zoster with idoxuridine. Scand J Infect Dis. 1981;13:257-62.
6. Jackson JL, Gibbons R, Meyer G, Inouye L. The effect of treating herpes zoster with oral aciclovir in preventing post-herpetic neuralgia: a metaanalysis. Arch Intern Med. 1997;157:909-12.
7. Choo PW, Galil K, Donahue JG, Walker AM, Spiegelman C, Platt R. Risk factors for postherpetic neuralgia. Arch Intrn Med. 1997;157:1217-24.
8. Wood MJ, Kay R, Dworkin RH, Soong S-J, Whitley RJ. Oral acyclovir therapy accelerates pain resolution in patients with herpes zoster: a metaanalysis of placebo-controlled trials. Clin Infect Dis. 1996;22:341-7.
9. Harrison RA, Soong S, Weiss HL, Gnann JW, Whitley RJ. A mixed model for factors predictive of pain in AIDS patients with herpes zoster. J Pain Symptom Manage. 1999; 17:410-7.
10. Whitley RJ, Weiss HL, Soong SJ, Gnann JW. Herpes zoster: risk categories for persistent pain. J Infect Dis. 1999; 179:9-15.
11. Dworkin RH, Schmader KE. Epidemiology and natural history of herpes zoster and post-herpetic neuralgia. En: Watson CPN, Gershon AA, editors. Herpes zoster and post-herpetic neuralgia. 2nd ed. New York: Elsevier Press; 2001. p. 39-64.
12. Johnson RW, Dworkin RH. Treatment of herpes zoster and postherpetic neuralgia. BMJ. 2003;326:748-50.
13. Gross G, Schöfer H, Wassilew S, et al. Herpes zoster guideline of the German Dermatology Society (DDG). J Clin Virol. 2003;26:277-89.
14. Meister W, Neiss A, Gross G, et al. A prognostic score for postherpetic neuralgia in ambulatory patients. Infection. 1998;26:359-63.
15. Board of the Australian Herpes Management Forum. Disponible en: http://www.ahmf.com.au
16. International Herpes Management Forum, pp 33-45, 58-68, 69-78 and 77-99. Disponible en: http://www.IHMF.org
17. Management of herpes zoster and postherpetic neuralgia. American Family Physician. Disponible en: http://aafp.org/afp/20000415/2437.html
18. Varicella Zoster Virus Research Foundation. Disponible en: http://www.vzvfoundation.org
19. Guidelines for the management of shingles. Report of a working group of the British Society for the Study of Infection (BSSI). J Infect. 19955;30:193-200.
20. International Herpes Management Forum: Regional Management Forums (online). Disponible en: http://www. ihmf.org/globallinks/wld-ita.asp
21. Volpi A, Gross G, Hercogova J, Johnson RW. Current management of herpes zoster. The european view. Am J Clin Dermatol. 2005;6:317-25.
22. Wood MJ, Shukla S, Fiddian AP, Crooks RJ. Treatment of acute herpes zoster: effect of early (< 48 h) versus late (48-72 h) therapy with acyclovir and valaciclovir on prolonged pain. J Infect Dis. 1998;178 Suppl 1:81-4.
23. Decroix J, Partsch H, Gonzalez R, et al. Factors influencing pain outcome in herpes zoster: an observational study with valaciclovir. J Eur Acad Dermatol Venereol. 2000;14:23-33.
24. Walther LE, Prosowsky K, Walther A, Gudziol H. Herpes zoster oticus: symptom constellation and serological diagnosis. Laryngorhinootologie. 2004;83:355-62.
25. Sklar SH, Blue WT, Alexandr EJ, Bodian CA. Herpes zoster: the treatment and prevention of neuralgia with adenosine monophosphate. JAMA. 1985;253:1427-30.
26. Gnann JW, Whitley RJ. Herpes zoster. N Engl J Med. 2002; 347:340-6.
27. Shafran SD, Tyring SK, Ashton R, et al. Once, twice, or three times daily famciclovir compared with aciclovir for the oral treatment of herpes zoster in immunocompetent adults: a randomized, multicenter, double-blind clinical trial. J Clin Virol. 2004;29:248-53.
28. Keam SJ, Chapman TM, Figgitt DP. Brivudin. Drugs. 2004; 64:2091-7.
29. De Clerq E, Descamps J, De Somer P, Barr PJ, Jones AS, Walker RT. (E)-5-(2 Bromovinyl)-2′-deoxyuridine: a potent and reactive antiherpes agent. Proc Natl Sci USA. 1979;76:2947-51.
30. Tyring SK, Beutner KR, Tucker BA, Anderson WC, Crooks RJ. Antiviral therapy for herpes zoster. Randomized, controlled clinical trial of valacyclovir, and famciclovir therapy in immunocompetent patients of 50 years and older. Arch Fam Med. 2000;9:863-9.
31. Wassilew SW, Wutzler P, on behalf of the Brivudin Herpes Zoster Study Group. Oral brivudin in comparison with acyclovir for improved therapy of herpes zoster in immunocompetent patients results of a randomized, double-blind, multicentered study. Antiviral Research. 2003;59: 49-56.
32. Wutzler P, Stubinski BM, Koch I. Brivudin compared to acyclovir in the treatment of acute herpes zoster: a randomized, doble-blind, multicenter trial. Fourth International Conference of Varicella, Herpes Zoster, Postherpetic neuralgia. La Jolla, USA; 2001. p. 3-5.
33. Wassilew SW, Wutzler P, Brivudin Herpes Zoster Study Group. Oral brivudin in comparison with acyclovir for herpes zoster: a survey study on postherpetic neuralgia. Antiviral Res. 2003;59:57-60.
34. Wassilew SW, on behalf of collaborative brivudin PHN study group. Birvudin compared with famciclovir in the treatment of herpes zoster: effects in acute disease and chronic pain in immunocompetent patients. A randomized, double-blind, multinational study. J Eur Acad Dermatol Venereol. 2005;19:47-55.
35. McKendrick MW, McGill JI, White JE, Wood MJ. Oral acyclovir in acute herpes zoster. BMJ. 1986;293:1529-32.
36. Kost RG, Strauss SE. Postherpetic neuralgia - pathogenesis, treatment and prevention. N Engl J Med. 1996;335:32-42.
37. Beutner KR, Friedman DJ, Forszpaniak C, Andersen PL, Wood MJ. Valaciclovir compared with acyclovir for improved therapy for herpes zoster in immunocompetent adults. Antimicrob Agents Chemother. 1995;39:546-53.
38. Tyring S, Barbarash RA, Nahlik JE, et al. Famciclovir for the treatment of acute herpes zoster: Effects on acute disease and postherpetic neuralgia: A randomized double-blind, placebo-controlled trial. Ann Intern Med. 1995; 123:89-96.
39. World Health Organization. Cancer pain relief. Aufl Genf. 1996. p. 2.
40. Whitley RJ, Weiss H, Gnann JW Jr, et al. Acyclovir with and without prednisone for the treatment of herpes zoster. Ann Intern Med. 1996;125:376-83.
41. Wood MJ, Johnson RW, McKendrick MW, Taylor J, Mandal BK, Crooks J. A randomized trial of acyclovir for 7 days of 21 days with and without prednisone for treatment of acute herpes zoster. N Engl J Med. 1994;330:896-900.
42. Bowsher D. The effects of pre-emptive treatment of post-herpetic neuralgia with amitriptyline: a randomized, double-blind, placebo-controlled trial. J Pain Symptom Manage. 1997;13:327-31.
43. Johnson RW. Herpes zoster in the immunocompetent patients: management of post-herpetic neuralgia. Herpes. 2003;10:38-45.
44. Frampton JE, Foster RH. Pregabalin: In the treatment of postherpetic neuralgia. Drugs. 2005;65:111-8.
45. McQuay HJ, Carroll D, Jadad AR, et al. Dextromethorphan for the treatment of neuropathic pain: a double-blind, randomized controlled crossover trial with integral n-of-1 design. Pain. 1994;59:127-33.
46. Nelson KA, Park KM, Robinovitz E, Tsigos C, Max MB. High-dose oral dextromethorphan versus placebo in painful diabetic neuropathy and postherpetic neuralgia. Neurology. 1997;48:1212-8.
47. Eide PK, Jorum E, Stubhaug A, Bremnes J, Breivik H. Relief of post-herpetic neuralgia with the N-methyl-D-aspartic acid receptor antagonist ketamine: a double-blind, cross-over comparison with morphine and placebo. Pain. 1994;58:347-54.
48. Milligan NS, Nash TP. Treatment of postherpetic neuralgia: a review of 77 consecutive cases. Pain. 1985;23:173-83.
49. Winnie AP, Hartwell PAW. Relationship between time of treatment of acute herpes zoster with sympathetic blockade and prevention of postherpetic neuralgia: clinical support for a new theory of the mechanism by which sympathetic blockade provides therapeutic benefit. Reg Anesth. 1993;18:277-82.
50. Kikuchi A, Kotani N, Sato T, Takamura K, Sakai I, Matsuki A. Comparative therapeutic evaluation of intrathecal versus epidural methylprednisolone for long-term analgesia in patients with intractable postherpetic neuralgia. Reg Anesth Pain Med. 1999;24:287-93.
51. Kotani N, Kushikata T, Hashimoto H, et al. Intrathecal methylprednisolone for intractable postherpetic neuralgia. N Engl J Med. 2000;343:1514-9.
52. Terrence CF, Fromm GH, Teniclo R. Baclofen as an analgesic in chronic peripheral nerve disease. Eur Neurol. 1985;24:380-5.
53. Harke H, Gretenkort P, Ladleif HU, Koester P, Rahman S. Spinal cord stimulation in postherpetic neuralgia and in acute herpes zoster pain. Anesth Analg. 2002;94:694-700.
54. Meglio M, Cioni B, Prezioso A, Talamonti G. Spinal cord stimulation (SCS) in the treatment of postherpetic pain. Acta Neurochir 1989;46 Suppl:65-6.
55. Kumar K, Toth C, Nath RK. Spinal cord stimulation for chronic pain in peripheral neuropathy. Surg Neurol. 1996; 46:363-9.
56. Petersen KL, Rice FL, Suess F, Berro M, Rowbotham MC. Relief of post-herpetic neuralgia by surgical removal of painful skin. Pain. 2002;98:119-26.
57. Kang FC, Chang PJ, Chen HP, Tsai YC. Patient-controlled epidural analgesia for postherpetic neuralgia in an HIV-infected patient as a therapeutic amblatoy modality. Acta Anaesthesiol Sin. 1998;36:235-8.
58. Bernstein JE, Korman NJ, Bickers DR, Dahl MV, Millikan LE. Topical capsaicin treatment of chronic postherpetic neuralgia. J Am Acad Dermatol. 1989;21:265-70.
59. Watson CP, Tyler KL, Bickers DR, Millikan LE, Smith S, Coleman E. A randomized vehicle-controlled trial of topical capsaicin in the treatment of postherpetic neuralgia. Clin Ther. 1993;15:510-26.
60. Petersen KL, Fields HL, Brennum J, Sandrini P, Rowbotham MC. Capsaicin evoked pain and allodynia in post-herpetic neuralgia. Pain. 2000;88:125-33.
61. Nolano M, Simone DA, Wendelshafer-Crabb G, Johnson T, Hazen E, Kennedy WR. Topical capsaicin in human. Parallel loss of epidermal nerve fibers and pain sensation. Pain. 1999;81:135-45.
62. Warson CP, Evans RJ, Watt VR. Post-herpetic neuralgia and topical capsaicin. Pain. 1988;33:333-40.
63. DeBenedittis G, Besana F, Lorenzetti A. A new topical treatment for acute herpetic neuralgia and postherpetic neuralgia: the aspirin diethyl ether mixture. An open label study plus a double-blind, controlled clinical trial. Pain. 1992;48:383-90.
64. King RB. Topical aspirin in chloroform and the relif of pain due to herpes zoster and postherpetic neuralgia. Arch Neurol. 1993;50:1046-53.
65. Tajti J, Szok D, Vecsei L. Topical acetylsalicilic acid versus lidocaine for postherpetic neuralgia: results of a double-blind comparative clinical trial. Neurobiology. 1999;7:103-8.
66. Alexander JL. Postherpetic neuralgia. Anaesthesia. 1985; 40:1133-4.
67. Coniam SW, Hunton J. A study of benzydamine cream in postherpetic neuralgia. Res Clin Forums. 1988;10:65-7.
68. McQuay HJ, Carroll D, Moxon A, Glynn CJ, Moore RA. Benzydamine cream for the treatment of post-herpetic neuralgia: minimun duration of treatment periods in a cross-over trial. Pain. 1990;40:131-5.
69. Rowbotham MC, Davies PS, Fields HL. Topical lidocaine gel relieves postherpetic neuralgia. Ann Neurol. 1995;37: 246-53.
70. Rowbotham MC, Davies PS, Verkempinck C, Galer BS. Lidocaine patch: double-blind study of a new treatment method for post-herpetic neuralgia. Pain. 1996;65:39-44.
71. Galer BS, Rowbotham MC, Perander J, Friedman E. Topical lidocaine patch relieves postherpetic neuralgia more effectively than a vehicle topical patch: results of an enriched enrollment study. Pain. 1999;80:533-8.
72. Katz NP, Gammaitoni AR, Davis MW, Dworkin RH, The Lidoderm Patch Study Group. Lidocaine patch 5% reduces pain intensity and interference with quality of life in patients with postherpetic neuralgia: an effectiveness trial. Pain Med. 2002;3:324-32.
73. Devers A, Galer BS. Topical lidocaine patch relieves a variety of neuropathic pain conditions: an open-label study. Clin J Pain. 2000;16:205-8.
74. Meno A, Arita H, Hanoka K. Preliminary report: the efficacy of clonidine hydrochloride ointment for postherpetic neuralgia. Masuri. 2001;50:160-3.
75. Cobo M, Foulks GN, Liesegang T, et al. Observations on the natural history of herpes zoster opthalmicus. Curr Eye Res. 1987;6:195-9.
76. Colin J, Prisant O, Cochener B, Lescale O, Rolland B, Hoang-Xuan T. Comparison of the efficacy and safety of valaciclovir and acyclovir for the treatment of herpes zoster opthalmicus. Opthalmology. 2000;107:1507-11.
77. Tyring S, Engst R, Corriveau C, et al. Famciclovir for opthalmic zoster: a randomized aciclovir controlled study. Br J Ophthalmol. 2001;85:576-81.
78. Colin J, Prisant O, Cochener B, Lescale O, Rolland B, Hoang-Xuan T. Comparison of the efficacy and safety of valaciclovir and acyclovir for the treatment of herpes zoster ophthalmicus. Ophthalmology. 2000;107:1507-11.
79. Hoang-Xuan T, Büchi R, Herbort CP, et al. Oral acuclovir for herpes zoster ophthalmicus. Ophthalmology. 1992;99: 1062-70.
80. Cockburn DM, Douglas IS. Herpes zoster ophthalmicus. Clin Exp Optom. 2000;83:2:59-64.
81. Higginbotham E, Lee DA. Management of difficult glaucoma. Boston: Blackwell; 1994. p. 131.
82. Sundmacher R. Therapie der viruserkrankungen des vorderen augenabschnittes. En: Kampik A, editor. Das äußere auge: Hauptreferate der XXXI - Essener Fortbildung für Augenärzte. Bücherei des Augenarztes. 1996;137:121-5.
83. Kleinschmidt-DeMasters BK, Amlie-Lefond C, Gilden DH. The patterns of varicella zoster virus encephalitis. Hum Pathol. 1996;27:927-38.
84. Gnann JW. Varicella-zoster virus: atypical presentations and unusual complications. J Infect Dis. 2002;186:S91-S8.
85. Nikkels AF, Nikkels-Tassoudji N, Pierard GE. Revisiting chilhood herpes zoster. Pediatr Dermatol. 2004;21:18-23.
86. Lagarde C, Steen AE, Bieber T, Steen KH. Zoster in chilhood after inapparent varicella. Acta Derm Venereol (Stockh). 2001;81:212-3.
87. Rothe M, Feder H, Grant-Kels J. Oral acuclovir therapy for varicella ans zoster infections in pediatric and pregnant patients: a brief review. Pediatr Dermatol. 1991;8:236-42.
88. Glesby MJ, Moore RD, Chaisson RE. Clinical spectrum of herpes zoster in adults infected with human immunodeficiency virus. Clin Infect Dis. 1995;21:370-5.
89. Dunic I, Djurkovic-Djakovic O, Vesic S, et al. Herpes zoster as an immune restoration disease in AIDS patients during therapy including protease inhibitors. Int J STD AIDS. 2005;16:475-8.
90. Wood MJ. Antivirals in the context of HIV disease. J Antimicrob Chemother. 1996;37 Suppl B:97-112.
91. Gnann JW, Crumpacker CS, Lalezari JP, et al. Sorivudine versus acyclovir for treatment of dermatomal herpes zoster in human immunodeficiency virus-infected patients: results from a ramdomized controlled clinical trial. Antimicrob Agents Chemother. 1998;42:1139-45.
92. Gnann JW, Whitley RJ. Herpes zoster. N Engl J Med. 2002; 347;340-6.
93. Herrero JI, Quiroga J, Sangro B, et al. Herpes zoster after liver transplantation: Incidence, risk factors ans complications. Liver Transpl. 2004;10:1140-3.
94. Safrin S, Berger TG, Gilson I, Wolfe PR, Wofsy CB. Foscarnet therapy in five patients with AIDS and acyclovir-resistant varicella-zostet vitus infection. Ann Intern Med. 1991;115:19-21.
95. Breton G, Fillet AM, Katlama C, Bricaire F, Caumes E. Acyclovir-resistant herpes zoster in human immunodeficiency virus-infected patients: results of foscarnet therapy. Clin Infect Dis. 1998;27:1525-7.
96. Reusser P. Management of viral infections in immunocompromised cancer patients. Swiss Med Wkly. 2002;132:374-8.
97. Redman RL, Nader S, Zerboni L, et al. Early reconstitution of immunity and decresed severity of herpes zoster in bone marrow transplant recipients immunized with inactived varicella vaccine. J Infect Dis. 1997;176:578-85.
98. Lundgren G, Wilczek H, Lonnqvist B, et al. Acyclovir prophylaxis in bone marrow transplant recipients. Scand J Infect Dis Suppl. 1985;47:137-44.
99. Tyring S, Belanger R, Bezwoda W, Ljungman P, Boon R, Saltzman RL, for the collaborative famciclovir immunocompromised study group. A randomized, double-blind trail of famciclovir versus acyclovir for the treatment of localized dermatomal herpes zoster in immunocompromised patients. Cancer Invest. 2001;19:13-22.
100. Christiansen NP, Haake RJ, Hurd DD. Early herpes zoster infection in adult patients with Hodgkin's disease undergoing autologous bone marrow transplant. Bone Marrow Transplant. 1991;7:435-7.
101. Han CS, Miller W, Haake R, Weisdorf D. Varicella zoster infection after bone marrow transplantation: Incidence, risk factors ans complications. Bone Marrow Transplant. 1994;13:277-83.
102. Reusser P. Management of viral infections. En: Klastersky J, Schimpff SC, Senn HJ, editors. Suportive care in cancer: a handbook for oncologist. 2nd ed. New York: Marcel Dekker; 1999. p. 87-112.
103. Balfour HH Jr. Antiviral drugs. N Engl J Med. 1999;340: 1255-68.
104. Saint-Leger E, Caumes E, Breton G, et al. Clinical and virological characterization of acyclovir-resistant varicella-zoster viruses isolated from 11 patients with acquired immunodeficiency syndrome. Clin Infect Dis. 2001;33: 2061-7.
105. Safrin S, Cherrington J, Jaffe HS. Clinical uses of cidofovir. Rev Med Virol. 1997;7:145-56.
106. Snoeck R, Andrei G, Clerq ED. Novel agents for the therapy of varicella-zoster infections. Expert Opin Investig Drugs. 2000;9:1743-51.
107. Goldman GS. Incidence of herpes zoster among children and adolescents in a community with moderate varicella vaccination coverage. Vaccine. 2003;21:4243-9.
108. Levin MJ, Smith JG, Kaufhold RM, et al. Decline in varicella-zoster virus (VZV)-specific cell-mediated immunity with increasing age and boosing with a high-hose VZV vaccine. J Infect Dis. 2003;188:1336-44.
109. Brisson M, Edmunds WJ, Gay NJ. Varicella vaccination: impact of vaccine efficacy on the epidemiology of VZV. J Med Virol. 2003;70:S31-S7.
110. Brisson M, Gay NJ, Edmunds WJ, Andrews NJ. Exposure to varicella boosts immunity to herpes-zoster: implications for mass vaccination against chickenpox. Vaccine. 2002; 20:2500-7.
111. Levin MJ, Barber D, Goldbart E, et al. Use of a live attenuated varicella vaccine to boost varicella-specific immune responses in seropositive people 55 years of age and older: duration of booster effect. J Infect Dis 1998;178:Suppl 1: 109-12.
112. Chapman RS, Cross KW, Fleming DM. The incidence of shingles and its implications for vaccination policy. Vaccine. 2003;21:2541-7.